
Tensive publishes positive long-term clinical follow-up data in Breast Cancer on REGENERA™ / SOFTAG™ breast implant
24-month Phase I follow-up data show positive outcomes are maintained High levels of investigator and patient satisfaction, excellent safety profile Ongoing registrational trial will yield top-line results before the end of 2025 Product could be approved …